Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.
The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure.
Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types.
The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for targets outside of Aktis’ proprietary pipeline.
